摘要
奥氮平属于第二代抗精神病药物,已被临床广泛应用,疗效显著。但随着应用时间的推进,临床发现服用奥氮平的患者出现体重增加、糖脂水平异常等代谢失衡的现象较多。药物性代谢失衡不仅是导致心血管疾病发生的危险因素,还会影响到患者的生活质量和用药依从性,导致病程迁延。因此,奥氮平致代谢失衡这一课题备受关注。本文综述了有关该问题的一些国内外干预措施研究进展,以期为临床及机制研究提供参考。
As one of the second-generation antipsychotics, Olanzapine has been widely used in clinic with remarkable curative effect. However, as the application time progressed, it has been found that the incidence of metabolism imbal- ance is relatively higher in patients taking olanzapine, such as weight gain and abnormal levels of glucose and lipid. Drug-induced metabolism imbalance is a risk faetor for cardiovascular disease and could affect the quality of life and patients＇ medication compliance resulting in prolonging the course of disease. Olanzapine-induced metabolism imbal- ance has attracted much attention, and this article reviews the＇domestic and research progress on interventions of this issue with the hope to provide reference for clinical and mechanism research.
出处
《中国医药导报》
CAS
2018年第4期43-46,共4页
China Medical Herald
基金
江苏省苏州市"科教兴卫"青年科技项目(kjxw2015034)
江苏省苏州市精神疾病临床医学中心项目(Szzx201509)
关键词
第二代抗精神病药物
奥氮平
代谢失衡
干预
Second-generation antipsychotics
Olanzapine
Metabolism imbalance
Intervention
